FLT3 Y572C

CI-VAR-00004825Explore in graph →NP_004110.2:p.Tyr572CysNM_004119.3:c.1715A>GClinVar 376328 CIViC 5401

Curated evidence

Evidence by cancer (14 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–14 of 14 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia14
FLT3 Y572C	(oncogenic)	Oncogenic	B	Supports Oncogenicity	5	submitted	EID12785 Ba/F3 cell lines engineered to express Y572C showed sustained growth in the absence of IL-3 similar to the FLT3-ITD cell line (Figure 2A). The Ba/F3 WT expressing cell line showed growth with additio… (full text at CIViC) PMID 39806020 · Anabtawi et al., 2025 · Open in CIViC	civic
FLT3 Y572C	(oncogenic)	Oncogenic	C	Supports Oncogenicity	1	submitted	EID13040 The paper includes 1660 newly diagnosed de novo AML cases on frontline CALGB and a total of 37 point mutations and deletions were identified in the juxtamembrane domain of the FLT3 gene. Three patient… (full text at CIViC) PMID 39806020 · Anabtawi et al., 2025 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.